Skip to main content

Advertisement

SpringerLink
Log in

Trastuzumab

  • Adis New Drug Profile
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

▴ Trastuzumab is a recombinant humanised monoclonal antibody specific for the growth factor receptor p185HER2 (HER2) which is overexpressed in 25 to 30% of breast cancer tumours.

▴ The drug inhibits the growth of human breast cancer cells overexpressing HER2 in vitro and in vivo. It shows additive antitumour activity in vitro and in vivo when administered with paclitaxel, doxorubicin, various cytokines or tamoxifen.

▴ In patients with metastatic breast cancer whose tumours overexpressed HER2, trastuzumab (4 mg/kg loading dose then 2 mg/kg/week by intravenous infusion) produced objective responses in 21% of 213 patients. A further 7% of patients had minor responses and 30% had stable disease.

▴ Combination therapy with trastuzumab and either paclitaxel or doxorubicin (or epirubicin) plus cyclophosphamide produced a higher response rate (49%), longer median time to disease progression (7.6 months), a higher one-year survival rate (78%) and significantly increased median overall survival (25.4 months) than antineoplastic agents alone (response rate 32%, time to disease progression 4.6 months, one-year survival rate 67% and overall survival 20.3 months) in a phase III study in 469 patients.

▴ Trastuzumab is generally well tolerated. Chills, fever, nausea, vomiting, weakness and headache were among the most common adverse events in clinical trials and occurred in 40 to 50% of patients during the first infusion of the drug. Cardiac dysfunction was the most serious adverse event reported and was more common in patients receiving trastuzumab plus antineoplastic therapy than in those receiving trastuzumab alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/ neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998 Aug; 16: 2659–71

    PubMed  CAS  Google Scholar 

  2. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 neu monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996 Mar; 14: 737–44

    PubMed  CAS  Google Scholar 

  3. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–12

    Article  PubMed  CAS  Google Scholar 

  4. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu. oncogene. Science 1987; 235: 177–82

    Article  PubMed  CAS  Google Scholar 

  5. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15: 2894–904

    PubMed  CAS  Google Scholar 

  6. Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993; 11: 1936–42

    PubMed  CAS  Google Scholar 

  7. Genentech I. FDA advisory committee recommends approval of first monoclonal antibody for metastatic breast cancer. In: Media Release 1998 Sep: [3pages],2

  8. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin™ enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998 Jul 1; 58: 2825–31

    PubMed  CAS  Google Scholar 

  9. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89: 4285–9

    Article  PubMed  CAS  Google Scholar 

  10. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18: 2241–51

    Article  PubMed  CAS  Google Scholar 

  11. Kopreski MS, Lipton A, Harvey HA, et al. Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines. Anticancer Res 1996 Jan–Feb; 16: 433–6

    PubMed  CAS  Google Scholar 

  12. Witters LM, Kumar R, Chinchilli VM, et al. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 1997 Jan; 42: 1–5

    Article  PubMed  CAS  Google Scholar 

  13. Lopez AM, Pegram MD, Landaw EM, et al. Models to assess combination therapy interactions: optimal timing of anti-HER-2 antibody and doxorubicin in breast cancer [abstract]. 88th Annu Meet Am Assoc Cancer Res 1997 Apr 12: 605

    Google Scholar 

  14. Park JW, Colbern G, Nuijens A, et al. Increased levels of circulating HER2 ECD in response to anti-HER2 antibody therapy [abstract]. Breast Cancer Res Treat 1997 Oct; 46: 67

    Google Scholar 

  15. Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of Herceptin™ (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer [abstract]. 34th Proc Am Soc Clin Oncol 1998 May 16; 17: 97

    Google Scholar 

  16. Genentech Inc. Herceptin® (trastuzumab) prescribing information. San Francisco (CA), 1998

  17. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin™ (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial [abstract]. 34th Proc Am Soc Clin Oncol 1998 May 16; 17: 98

    Google Scholar 

  18. Baselga J, for the Herceptin International Investigator Group. Multinational studies of HerceptinTM (humanized anti-HER2 antibody) in HER+ metastatic breast cancer: Phase III of Herceptin plus chemotherapy (CRx) vs CRx alone in first-line and large phase II of Herceptin alone in advanced disease. Ann Oncol 9 (Suppl. 2)

  19. Data on file. Hoffmann-La Roche, Basel. 1999

  20. Norton L, Slamon D, Leyland Jones B, et al. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody herceptin in HER2-overexpressing metastatic breast cancer [abstract]. 35th Am Soc Clin Oncol 1999; 18: 127

    Google Scholar 

  21. Sliwkowski MX, Fox JA, Twaddell T et al. A humanized monoclonal antibody for the treatment of HER2 overexpressing breast cancer [abstract]. 87th Annu Meet Am Assoc Cancer Res 1996 Apr 20: 625-6

    Google Scholar 

  22. FDA clears Herceptin at record speed. Scrip Mag 1998; 2374: 20

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Caroline M. Perry & Lynda R. Wiseman

Authors
  1. Caroline M. Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lynda R. Wiseman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caroline M. Perry.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perry, C.M., Wiseman, L.R. Trastuzumab. BioDrugs 12, 129–135 (1999). https://doi.org/10.2165/00063030-199912020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199912020-00004

Keywords

Search

Navigation